← Back to Search

Relational Agent (RA) for Colorectal Cancer (CATALYST Trial)

Q: What is the current number of participants being enrolled in this clinical study?

<p>Indeed, according to the details provided on clinicaltrials.gov, this trial is actively seeking eligible candidates. The initial posting of the trial was made on October 26th, 2023 and the most recent update occurred on December 15th, 2023. The study aims to enroll a total of 56 participants at one designated site.</p>

Q: Is the enrollment for this clinical trial currently open?

<p>Indeed, the information provided on clinicaltrials.gov confirms that this ongoing clinical trial is actively seeking eligible participants. The trial was initially posted on October 26, 2023 and subsequently updated on December 15, 2023. Recruitment aims to enroll a total of 56 patients from a single location.</p>

Phase < 1

Recruiting

Led By Anita Y Kinney, PhD, RN

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial, or prostate cancer

Have not previously undergone GT for hereditary cancer predisposition

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1-month, 6-months

Awards & highlights

CATALYST Trial Summary

This trial aims to improve genetic education and testing for cancer survivors who may have a hereditary risk of cancer. The study will focus on developing and testing a digital intervention called CATALYST, which will

Who is the study for?

This trial is for cancer survivors with specific cancers such as breast, ovarian, prostate, colorectal and pancreatic. Participants should be interested in learning about their genetic risk of cancer through testing and education using smart technology.Check my eligibility

What is being tested?

The study tests a digital tool called CATALYST (a relational assistant) against enhanced usual care to see if it improves genetic education and testing uptake among cancer survivors. Participants will be randomly placed into one of these two groups.See study design

What are the potential side effects?

Since this is an observational study focusing on educational tools rather than medical treatments, traditional physical side effects are not applicable. However, participants may experience emotional or psychological impacts from learning about their genetic risks.

CATALYST Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a specific type of cancer.

Select...

I have never had gene therapy for inherited cancer risk.

Select...

I was diagnosed with specific cancers at a certain age or have a high-risk prostate cancer.

Select...

I am 18 years old or older.

CATALYST Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1-month, 6-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1-month, 6-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-month, 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants with Genetic Testing Uptake

Secondary outcome measures

Acceptance and Usability of the Relational Agent

CATALYST Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Relational Agent (RA)Experimental Treatment1 Intervention

RA participants will be provided with access to Alex, the RA. After completing the RA, RA participants can proceed directly to GT.

Group II: Enhanced Usual Care (EUC)Active Control1 Intervention

EUC participants will be sent a clinical letter informing them of their increased risk of hereditary cancer, availability of GC and GT services, and contact information to schedule an appointment with a genetic counselor at the LIFE Center.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor

429 Previous Clinical Trials

64,176 Total Patients Enrolled

Anita Y Kinney, PhD, RNPrincipal InvestigatorDirector, Center for Cancer Health Equity

5 Previous Clinical Trials

1,305 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of participants being enrolled in this clinical study?

"Indeed, according to the details provided on clinicaltrials.gov, this trial is actively seeking eligible candidates. The initial posting of the trial was made on October 26th, 2023 and the most recent update occurred on December 15th, 2023. The study aims to enroll a total of 56 participants at one designated site."

Answered by AI

Is the enrollment for this clinical trial currently open?

"Indeed, the information provided on clinicaltrials.gov confirms that this ongoing clinical trial is actively seeking eligible participants. The trial was initially posted on October 26, 2023 and subsequently updated on December 15, 2023. Recruitment aims to enroll a total of 56 patients from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Choices About Genetic Testing And Learning Your Risk With Smart Technology

Anita Y. Kinney, PhD, RN 2023. "Choices About Genetic Testing And Learning Your Risk With Smart Technology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06184867.